MNTA Share Price

Open 14.25 Change Price %
High 14.65 1 Day 0.20 1.40
Low 14.05 1 Week 0.35 2.47
Close 14.50 1 Month 1.90 15.08
Volume 864464 1 Year -1.83 -11.21
52 Week High 16.95
52 Week Low 0.00
MNTA Important Levels
Resistance 2 15.06
Resistance 1 14.83
Pivot 14.40
Support 1 14.17
Support 2 13.94
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)

MNTA Technical Analysis 5
As on 8th Dec 2016 MNTA Share Price closed @ 14.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 11.26 & Strong Buy for SHORT-TERM with Stoploss of 12.54 we also expect STOCK to react on Following IMPORTANT LEVELS.
MNTA Target for December
1st Target up-side 16.41
2nd Target up-side 17.99
3rd Target up-side 19.57
1st Target down-side 11.89
2nd Target down-side 10.31
3rd Target down-side 8.73
MNTA Other Details
Segment EQ
Market Capital 681705792.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.momentapharma.com
MNTA Address
MNTA
675 West Kendall Street
Cambridge, MA 02142
United States
Phone: 617-491-9700
Fax: 617-621-0431
Interactive Technical Analysis Chart Momenta Pharmaceuticals, Inc. ( MNTA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Momenta Pharmaceuticals, Inc.
MNTA Business Profile
Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). This results in a diversified product pipeline of complex generic, follow-on biologic (FOB) and novel drugs. The Company�s complex generic programs target marketed products, which were originally approved by the United States Food and Drug Administration (FDA) as New Drug Applications (NDAs). Its M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). During the year ended December 31, 2011, it acquired the assets of Virdante. On February 13, 2012 it entered into a global collaboration (Baxter Agreement) with Baxter International Inc.